MALARIA VACCINE

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

12793575

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region. Moreover, when the animals were injected with a mixture of GLURP and MSP3, individual mice tended to mount a predominant antibody response against either molecule: in some animals GLURP was immunodominant whereas in other animals MSP3 was the dominant immunogen. Additionally, the hybrid was also more antigenic than the individual recombinant proteins since the ELISA-titer of naturally occurring IgG antibodies, in clinically

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STATENS SERUM INSTITUT5 ARTILLERIVEJ COPENHAGEN S 2300

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
JEPSEN, SØREN HOLTE, DK 2 0
THEISEN, MICHAEL FREDERIKSBERG C, DK 10 43

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation